Unicancer
Guillaume Demarez is an accomplished professional in information systems security, currently serving as Responsable de la Sécurité des Systèmes d'Information at Unicancer since February 2023. Previously, Guillaume held the same position at GOJO Industries-Europe Ltd from June 2018 to January 2023, focusing on protecting enterprise activities and addressing daily security challenges. Prior to that, Guillaume worked as Administrateur réseau et systèmes at Laboratoires Prodène Klint and GDE77, where responsibilities included ensuring system functionality and resolving IT issues across diverse contexts. Early career experiences include roles as a Technicien/Formateur at Millenium Informatique and Technicien support at Teleperformance, specializing in network issues. Guillaume holds a DUT in Génie des Télécommunications et Réseaux from IUT de Reims-Châlons-Charleville and a BAC in Sciences et Techniques Industrielles from Lycée St Jean-Baptiste de la Salle.
This person is not in the org chart
This person is not in any teams
Unicancer
UNICANCER groups together the 20 French Comprehensive Cancer Centres (FCCCs) which are private, not-for-profit hospitals located across the French territory. FCCCs are dedicated to fighting cancer through a threefold mission of patient care, research and education. They contribute to the public hospital service in accordance with statutory fees, with no additional charge. UNICANCER is one of the largest cancer care and research organisations in Europe. Via its R&D department, it sponsors clinical trials to improve cancer patients’ care and access to innovation, particularly in areas neglected by the pharmaceutical industry. UNICANCER is accredited by the French Ministry of Health and is eligible for public grants. The French Comprehensive Cancer Centres in numbers: • 20 sites located throughout the French territory • 19,000 employees • >135,000 patients hospitalised each year • Approximately 500 active clinical trials • 17% of the patients treated are included in a clinical trial (vs an average of 8.5% of cancer patients in France) • 19 molecular biology platforms certified by the French National Cancer Institute • 7 integrated cancerology research sites (SIRIC) certified by the French NCI (out of 8) • 12 early-phase clinical trial Centres (CLIP²) certified by the French NCI (out of 16) • 5th for global publications in oncology • 32% of French publications in oncology (articles in which FCCCs have participated) UNICANCER sponsors • 76 ongoing clinical trials (2016) • Including 5400 patients (2016) • From 270 investigator sites (2015), • With 20% located in other European countries